| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
1 Department of Medical Biochemistry, Graduate School of Medical Science and 2 Station-II for Collaborative Research, Kyushu University; 3 Third Department of Medicine, Fukuoka University School of Medicine, Fukuoka, Japan; 4 First Department of Pathology, Asahikawa Medical College, Asahikawa, Japan; and 5 Research Center for Innovative Cancer Therapy of the 21st Century Center of Excellence Program for Medical Science, Kurume University, Kurume, Japan
Requests for reprints: Mayumi Ono, Department of Medical Biochemistry, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, 812-8582 Fukuoka, Japan. Phone: 81-92-642-6098; Fax: 81-92-642-6203; E-mail: mayumi{at}biochem1.med.kyushu-u.ac.jp.
Hepatocellular carcinoma (HCC) is one of the most common tumor-related causes of death worldwide for which there is still no satisfactory treatment. We previously reported the antiangiogenic effect of gefitinib, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has been used successfully to treat lung cancer. In this study, we investigated the effects of gefitinib on tumor-induced angiogenesis by using HCC cell lines (HCC3, CBO12C3, and AD3) in vitro as well as in vivo. Oral administration of gefitinib inhibited angiogenesis induced by HCC3 and CBO12C3, but not by AD3 in the mouse dorsal air sac model. Production of both vascular endothelial growth factor (VEGF) and chemokine C-X-C motif ligand 1 (CXCL1) by EGF-stimulated HCC was more markedly inhibited by gefitinib in HCC3 and CBO12C3 cells than in AD3 cells. EGF stimulated the phosphorylation of EGFR, Akt, and extracellular signal-regulated kinase 1/2 (ERK1/2) in HCC3 and CBO12C3 cells, whereas EGF stimulated phosphorylation of EGFR and ERK1/2, but not Akt in AD3 cells. In fact, Akt was constitutively activated in the absence of EGF in AD3 cells. Gefitinib inhibited Akt phosphorylation in all three cell lines, but it was about five times less effective in AD3 cells. The concentration of PTEN in AD3 cells was about a half that in HCC3 and CBO12C3 cells. Transfection of HCC3 cells with PTEN small interfering RNA reduced their sensitivity to gefitinib in terms of its inhibitory effect on both Akt phosphorylation and the production of VEGF and CXCL1. In conclusion, effect of gefitinib on HCC-induced angiogenesis depends on its inhibition of the production of angiogenic factors, probably involving a PTEN/Akt signaling pathway. (Cancer Res 2006; 66(10): 5346-53)
This article has been cited by other articles:
![]() |
I. Jorge, P. Navarro, P. Martinez-Acedo, E. Nunez, H. Serrano, A. Alfranca, J. M. Redondo, and J. Vazquez Statistical Model to Analyze Quantitative Proteomics Data Obtained by 18O/16O Labeling and Linear Ion Trap Mass Spectrometry: Application to the Study of Vascular Endothelial Growth Factor-induced Angiogenesis in Endothelial Cells Mol. Cell. Proteomics, May 1, 2009; 8(5): 1130 - 1149. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q.-S. Zhu, W. Ren, B. Korchin, G. Lahat, A. Dicker, Y. Lu, G. Mills, R. E. Pollock, and D. Lev Soft Tissue Sarcoma Cells Are Highly Sensitive to AKT Blockade: A Role for p53-Independent Up-regulation of GADD45{alpha} Cancer Res., April 15, 2008; 68(8): 2895 - 2903. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Werth, D. Stuhlmann, B. Cat, H. Steinbrenner, L. Alili, H. Sies, and P. Brenneisen Stromal resistance of fibroblasts against oxidative damage: involvement of tumor cell-secreted platelet-derived growth factor (PDGF) and phosphoinositide 3-kinase (PI3K) activation Carcinogenesis, February 1, 2008; 29(2): 404 - 410. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nakao, Y. Hata, M. Miura, K. Noda, Y. N. Kimura, S. Kawahara, T. Kita, T. Hisatomi, T. Nakazawa, Y. Jin, et al. Dexamethasone Inhibits Interleukin-1{beta}-Induced Corneal Neovascularization: Role of Nuclear Factor-{kappa}B-Activated Stromal Cells in Inflammatory Angiogenesis Am. J. Pathol., September 1, 2007; 171(3): 1058 - 1065. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ono and M. Kuwano Molecular Mechanisms of Epidermal Growth Factor Receptor (EGFR) Activation and Response to Gefitinib and Other EGFR-Targeting Drugs Clin. Cancer Res., December 15, 2006; 12(24): 7242 - 7251. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |